Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
2025: Novo Nordisk announced positive Phase 3 ESSENCE trial results for semaglutide in early Alzheimer's disease, reporting statistically significant slowing of cognitive and functional decline a breakthrough data package that could establish GLP-1 therapy as a neuroprotective agent and open an addressable market of 6.5 million Alzheimer's patients in the U.S
Learn more about C12-15 Alkyl Benzoate Cyclohexasiloxane is a type of silicone more commonly known as D6
Figure 3: Structure of sitagliptin (Dibbern HW, et al ., 2002) Figure 4: Sitagliptin mechanism of action (Makrilakis K, 2019) Repaglinide Type 2 diabetes treatment with a BCS class II medication
With the ongoing pipeline of oral formulations and combination therapies, the GLP-1 market is expected to evolve into a cornerstone of endocrine and metabolic medicine
US$ 20.68
US$ 29.90
US$ 25.45
US$ 25.00
US$ 21.29
US$ 28.91
